echinocandin-b and Pneumocystis-Infections

echinocandin-b has been researched along with Pneumocystis-Infections* in 1 studies

Other Studies

1 other study(ies) available for echinocandin-b and Pneumocystis-Infections

ArticleYear
Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Nov-01, Volume: 43, Issue:9

    Echinocandins are a novel class of antifungal drugs that target beta (1, 3)-D-glucan synthesis. Animal studies have shown that these agents have activity against Pneumocystis jiroveci infection; however, clinical data are lacking. We reviewed all cases of proven P. jiroveci pneumonia (PCP) in non-human immunodeficiency virus-infected patients at our hospital over a 5 year period (2001-2005). Two patients received conventional PCP treatment and concomitant use of echinocandins for presumed invasive aspergillus. In both cases, PCP progressed, and the patient died. The use of echinocandins in the prevention or treatment of PCP cannot be recommended without evidence to support their effectiveness.

    Topics: Adolescent; Adult; Antifungal Agents; Disease Progression; Echinocandins; Female; Fungal Proteins; Humans; Male; Peptides, Cyclic; Pneumocystis carinii; Pneumocystis Infections; Treatment Failure

2006